PubMed Health⌕ Search

PubMed · 9735116

Primary immunodeficiency disorders.

Abstract

The primary immunodeficiency diseases are a relatively rare group of congenital disorders that are linked by the expression of an excessive number, duration, or severity of infections. The clinical features of most of the primary immunodeficiency diseases have been well described by astute physicians over several decades and have provided important clues to our basic understanding of human immunology. In contrast, the genetic basis and potential life-saving therapies for many of these disorders have been established only over the past few years. These recent advances have resulted in the prognosis of many of these disorders being largely dependent on their rapid recognition and treatment. Increased awareness of the differentiating epidemiologic, clinical, laboratory and genetic features of these diseases hold the promise of both furthering our understanding of basic human immunology and providing improved care for this challenging group of patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R J Mamlock. 1998. Primary immunodeficiency disorders.. https://doi.org/10.1016/s0095-4543(05)70085-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses.

The course of HIV infection varies widely among individuals. Long-term nonprogressors or slow progressors may remain asymptomatic and have normal CD4 counts despite more than a decade of untreated HIV infection. In contrast, rapid progressors develop AIDS within 5 years. In addition, some persons remain uninfected despite repeated exposure to HIV. Immunologic and genetic studies of long-term nonprogressors and exposed yet uninfected persons, as well as data from studies of primary HIV infection, have helped to elucidate the mechanisms by which some persons are protected from HIV acquisition or have slow rates of disease progression. This review (the first of two parts) describes what is currently known about host factors in HIV-1 infection. Studies for inclusion were identified by a systematic search of PubMed for English-language literature published from 1988 through June 2000. Abstracts of presentations at major meetings convened in 2000 were also included if appropriate. Growing evidence suggests a crucial role of cytotoxic T cells and T-helper cells in controlling viremia, slowing disease progression, and perhaps preventing establishment of infection. Humoral and mucosal immunity, soluble inhibitory factors, the cytokine milieu, and concomitant infections also affect outcome. Genetic host factors, such as inheritance of mutant chemokine receptors or certain HLA types, affect susceptibility to infection and subsequent clinical course. The role of cellular and humoral immunity, mucosal immunity, and other local factors in determining the course of HIV infection is discussed.

Antibody Formation↗

Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease.

The role of hepatitis C virus (HCV)-specific CD4+ T cells in recurrent HCV infection after orthotopic liver transplantation (OLTx) is unclear. In parallel, 73 intrahepatic and 73 blood-derived T cell lines were established from 34 patients. At a single cell level, virus-specific interferon (IFN)-gamma production to various HCV proteins was determined by ELISPOT assay: 45 (62%) of 73 liver- or blood-derived T cell lines produced IFN-gamma in response to one of the HCV antigens. HCV specificity was detected mainly in the liver (47% vs. 23% in the blood; P<.05, chi(2) test) and was detectable earlier (< or =6 months) significantly more often than later (>6 months) after OLTx (78% vs 49%; P<.05, chi(2) test). Histology, histologic activity index, liver enzymes, and virus load did not correlate with the occurrence of HCV-specific CD4+ T cells. Despite strong immunosuppressive treatment, OLTx recipients can develop an early, multispecific, preferentially intrahepatic CD4+ T cell response that decreases over time, making it a potential candidate target for novel therapeutic approaches in the transplant setting.

Antibody Formation↗